Female Sexual Arousal Disorder

 Print This Post

A new central nervous system drug for female sexual desire disorder has just completed the first two clinical trials. The name of the drug is Bremelanotide. In the group taking the drug 67% reported feelings of desire vs. 22% of the placebo group (the most common placebo effect is about 20% no matter what is being tested). 72% of those taking the drug had genital sexual arousal vs. 39% in the placebo group. In summary 75% of the women taking the drug reported sexual arousal and 50% had increased sexual desire vs. 25% and 19% respectively.